



### **How to Read This Supplemental Report**

The SARS-CoV-2 variant therapeutic data in this report have been curated in collaboration with the National Institutes of Health (NIH) <u>Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Tracking Resistance and Coronavirus Evolution (TRACE) Working Group with support from the Foundation for the National Institutes of Health (FNIH). New and updated information will be added on a weekly basis as more studies are shared. Please continue to check back as our curated database grows. Please contact us at NCATSOpenDataPortal@nih.gov with any feedback, comments, or questions to help us improve this resource.</u>

#### What Data is Included?

The underlying data in these visualizations has been curated, in collaboration with ACTIV TRACE, from a prioritized set of publications (both preprints and peer-reviewed articles). To improve data accuracy, publications are limited to prominent therapeutic agents (both approved and in clinical trial), with an emphasis on studies conducted 1) by the sponsoring pharmaceutical company or 2) with a government partner. The OpenData Portal does not intend to serve as a comprehensive dashboard for all variant therapeutic data published in the literature.

### **How to Interpret the Visualizations**

The visualization graphics are meant to provide a quick-glance summary of how **individual SARS-CoV-2 variants** may respond to known therapeutics, compared to reference strains. The displayed fold-change values represent data collected from published *in vitro* viral neutralization assays comparing variants to a reference strain.

**Of important note**, the data displayed were generated:

- · From different assay types and conditions
- By different research laboratories
- Using different reference strains
- With test material from different sources/of potentially different grades, tested at different dose ranges

As a result, the visualizations **should not be used to conduct side-by-side comparisons** of therapeutics. Reported minimum fold reduction values (e.g. >1000-fold) may have greater actual fold change values than those displayed. Furthermore, the data shown are collected from *in vitro* assays, and it is not known how *in vitro* neutralization assay data correlate with clinical outcomes. It is worth noting that the experimental therapeutic concentrations are not necessarily correlated to clinical concentrations; thus therapeutics with large reported fold reductions in activity **may still be active against the variants in clinical settings**, as standard dosing/exposure in patients could exceed the required therapeutic window. Lastly, the data may be from preliminary reports that **have not been peer reviewed** and thus should not be regarded as conclusive, guide clinical practice or health decisions, or be reported in news media as established information.

It is important to note that the fold-reduction values displayed are normalized and may differ from the original activity or fold-change values reported in preprints and publications. All values are normalized to express the fold reduction of neutralization activity for a specific therapeutic against a SARS-CoV-2 variant strain relative to an ancestral or reference SARS-CoV-2 strain within the same assay under identical conditions. The greater the fold-reduction value, the greater the reported reduction of neutralization activity of a specific therapeutic agent against a SARS-CoV-2 variant, compared to the wild-type control. Data with fold-reduction values between 0 and 1 indicate that the therapeutic agent displayed greater neutralization of the variant strain than the wild-type strain.

Interactive versions of these graphics are available on the OpenData Portal Visualization Page Additional details on the visualized data are available on the NCATS OpenData Portal.

## New to the OpenData Portal Variant Database this week:


### **New Pre-prints, Publications & Datasets:**

- 1. SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial [Pre-print]
- 2. <u>Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomized, dose-finding, multi-centered study [Pre-print]</u>
- 3. <u>An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam [Peer-reviewed publication]</u>
- 4. Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report [Pre-print]

#### **Updated Pre-prints, Publications & Datasets:**

 The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 [Pre-print]

### **Explore the latest Variants & Therapeutics data on OpenData Portal:**




#### Click to explore variant data on OpenData Portal:

What's new in the last week?		Data for All Variants			
B.1.1.7	B.1.351	B.1.617.2	B.1.621	AY.1/2	P.1
B.1.427/429	B.1.525	B.1.526	B.1.617	C.37	P.2
Other Variants		Single Point Mutation Data			





# In vitro data added to NCATS OpenData Portal in last week





10.18.2021

